BioCryst Pharmaceuticals (BCRX -8.7%) plunges on increased volume, triggering a volatility halt, in sympathy with the drop in Gilead Sciences (GILD -5.0%) on reports that a China-based study testing antiviral remdesivir failed to demonstrate a treatment benefit.
BioCryst is testing its own antiviral, galidesivir, for the same use. A Phase 1 study in Brazil is in process.
https://seekingalpha.com/news/3563784-biocryst-feels-gileads-remdesivir-pain-down-9
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.